

## **Ophthalmological Conditions**

1. Li L, Yu Y, Lin S, Hu J. Changes in best-corrected visual acuity in patients with dry age-related macular degeneration after stem cell transplantation: systematic review and meta-analysis. *Stem Cell Res Ther.* 2022 Jun 7;13(1):237. doi: 10.1186/s13287-022-02931-y. PmiD: 35672801; PMCID: PMC9172101.
2. Calonge M, Pérez I, Galindo S, Nieto-miguel T, López-Paniagua M, Fernández I, Alberca M, García-Sancho J, Sánchez A, Herreras JM. A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. *Transl Res.* 2019 Apr;206:18-40. doi: 10.1016/j.trsl.2018.11.003. Epub 2018 Nov 22. PmiD: 30578758.
3. Møller-Hansen M, Larsen AC, Toft PB, Lynggaard CD, Schwartz C, Bruunsgaard H, Haack-Sørensen M, Ekblond A, Kastrup J, Heegaard S. Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease. *Ocul Surf.* 2021 Jan;19:43-52. doi: 10.1016/j.jtos.2020.11.013. Epub 2020 Nov 28. PmiD: 33253910.
4. Figueiredo FC, Glanville JM, Arber M, Carr E, Rydevik G, Hogg J, Okonkwo A, Figueiredo G, Lako M, Whiter F, Wilson K. A systematic review of cellular therapies for the treatment of limbal stem cell deficiency affecting one or both eyes. *Ocul Surf.* 2021 Apr;20:48-61. doi: 10.1016/j.jtos.2020.12.008. Epub 2021 Jan 4. PmiD: 33412337.
5. Weiss JN, Levy S. Stem cell ophthalmology treatment study (SCOTS): bone marrow-derived stem cells in the treatment of Stargardt disease. *Medicines.* 2021 Feb 3;8(2):10.
6. Weiss JN, Levy S. Stem cell ophthalmology treatment study (SCOTS): bone marrow-derived stem cells in the treatment of age-related macular degeneration. *Medicines.* 2020 Mar 28;7(4):16.
7. Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy. *Stem Cell Investig* 2019;6:41.
8. Tuekprakhon A, Sangkitporn S, Trinavarat A, Pawestri AR, Vamvanij V, Ruangchainikom M, Luksanapruksa P, Pongpaksupasin P, Khorchai A, Dambua A, Boonchu P, Yodtup C, Uiprasertkul M, Sangkitporn S, Atchaneeeyasakul LO. Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa. *Stem Cell Res Ther.* 2021 Jan 9;12(1):52. doi: 10.1186/s13287-020-02122-7. PmiD: 33422139; PMCID: PMC7796606.

9. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbalstem-cell therapy and long-term corneal regeneration. *N Engl J Med.* 2010 Jul8;363(2):147-55. doi: 10.1056/NEJMoa0905955. Epub 2010 Jun 23. PubMed PMID:20573916.
10. Schwartz SD, Regillo CD, Lam BL, Elliott D, Rosenfeld PJ, Gregori NZ, HubschmanJP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM,Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stemcell-derived retinal pigment epithelium in patients with age-related maculardegeneration and Stargardt's macular dystrophy: follow-up of two open-label phase1/2 studies. *Lancet.* 2015 Feb 7;385(9967):509-16. doi:10.1016/S0140-6736(14)61376-3. Epub 2014 Oct 15. PubMed PMID: 25458728. <https://www.ncbi.nlm.nih.gov/pubmed/25458728>"
11. Song WK, Park KM, Kim HJ, Lee JH, Choi J, Chong SY, Shim SH, Del Priore LV,Lanza R. Treatment of macular degeneration using embryonic stem cell-derivedretinal pigment epithelium: preliminary results in Asian patients. *Stem CellReports.* 2015 May 12;4(5):860-72. doi: 10.1016/j.stemcr.2015.04.005. Epub 2015Apr 30. PubMed PMID: 25937371; PubMed Central PMCID: PMC4437471.
12. da Cruz L, Fynes K, Georgiadis O, Kerby J, Luo YH, Ahmado A, Vernon A, DanielsJT, Nommiste B, Hasan SM, Gooljar SB, Carr AF, Vugler A, Ramsden CM, Bictash M,Fenster M, Steer J, Harbinson T, Wilbrey A, Tufail A, Feng G, Whitlock M, Robson AG, Holder GE, Sagoo MS, Loudon PT, Whiting P, Coffey PJ. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-relatedmacular degeneration. *Nat Biotechnol.* 2018 Apr;36(4):328-337. doi:10.1038/nbt.4114. Epub 2018 Mar 19. PubMed PMID: 29553577. <https://www.ncbi.nlm.nih.gov/pubmed/29553577>"
13. Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, Fujihara M, Akimaru H, Sakai N, Shibata Y, Terada M, Nomiya Y, Tanishima S, Nakamura M, KamaoH, Sugita S, Onishi A, Ito T, Fujita K, Kawamata S, Go MJ, Shinohara C, Hata KI, Sawada M, Yamamoto M, Ohta S, Ohara Y, Yoshida K, Kuwahara J, Kitano Y, Amano N, Umekage M, Kitaoka F, Tanaka A, Okada C, Takasu N, Ogawa S, Yamanaka S, TakahashiM. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. *N Engl J Med.* 2017 Mar 16;376(11):1038-1046. doi: 10.1056/NEJMoa1608368. PubMedPMID: 28296613. <https://www.ncbi.nlm.nih.gov/pubmed/28296613>.

14. Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. *Invest Ophthalmol Vis Sci.* 2015 Jan 6;56(1):81-9. doi: 10.1167/iovs.14-15415. PubMed PMID: 25491299; PubMed Central PMCID: PMC4288143.
15. Tsubota K, Satake Y, Kaido M, Shinozaki N, Shimmura S, Bissen-miyajima H, Shimazaki J. Treatment of severe ocular-surface disorders with corneal epithelialstem-cell transplantation. *N Engl J Med.* 1999 Jun 3;340(22):1697-703. PubMed PMID: 10352161. <https://www.ncbi.nlm.nih.gov/pubmed/10352161>"
16. Tsubota K, Satake Y, Kaido M, Shinozaki N, Shimmura S, Bissen-miyajima H, Shimazaki J. Treatment of severe ocular-surface disorders with corneal epithelialstem-cell transplantation. *N Engl J Med.* 1999 Jun 3;340(22):1697-703. PubMed PMID: 10352161. <https://www.ncbi.nlm.nih.gov/pubmed/10352161>"
17. Özmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results. *Stem Cell Res Ther.* 2020 Aug 12;11(1):353. doi: 10.1186/s13287-020-01870-w. PMID: 32787913; PMCID: PMC7425139.
18. El Zarif M, Alió JL, Alió Del Barrio JL, Abdul Jawad K, Palazón-Bru A, Abdul Jawad Z, De Miguel MP, Makdiss N. Corneal Stromal Regeneration Therapy for Advanced Keratoconus: Long-term Outcomes at 3 Years. *Cornea.* 2021 Jun 1;40(6):741-754. doi: 10.1097/ICO.0000000000002646. PMID: 33591032.
19. Kahraman NS, Öner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial. *International Journal of Ophthalmology.* 2020;13(9):1423.
20. Kahraman NS, Öner A. Umbilical cord-derived mesenchymal stem cell implantation in patients with optic atrophy. *European Journal of Ophthalmology.* 2021 Nov;31(6):3463-70.
21. Abukhalil F, Lam BL, Guy J. Visual Observations of an American Patient With Leber Hereditary Optic Neuropathy After Purported Injections of Stem Cells in China. *Arch Ophthalmol.* 2012;130(4):532–534. doi:10.1001/archophthalmol.2011.1665